Astellas Wins Expanded Label to Include Pediatric Use for Oral Solifenacin in the EU

Tokyo-based Astellas Pharma (TYO: 4503) has been awarded EU approval for its neurogenic detrusor overactivity (NDO) therapy solifenacin succinate in oral suspension form. The drug is indicated for children aged 2 to 18 years. NDO is a bladder dysfunction in which increased storage pressure can put the upper urinary tract at risk of deterioration. Commonly observed in patients with conditions such as multiple sclerosis and spinal cord injury, it causes urinary incontinence in approximately 50% of MS patients. Read more.

Source: The Pharma Letter, March 9, 2018

Prescription Drugs for Overactive Bladder (OAB)

There are several prescription drugs for overactive bladder (OAB).

The FDA approved medications, or drugs, currently available on the U.S. market for the treatment of urinary incontinence are for a specific condition called overactive bladder (OAB). Some are also used for OAB with urge urinary incontinence (UUI). You may have seen advertisements on television or in magazines for these medications. Most of the prescription drugs for OAB partially calm the bladder muscles that cause abnormal contractions, thereby reducing the frequency and severity of the overwhelming urge to urinate. Some of these drugs may also increase the bladder’s capacity to hold urine and delay the initial urge to void. This class of drugs is referred to as antimuscarinics.

Continue reading→